Corient Private Wealth LLC Buys 163 Shares of Glaukos Co. (NYSE:GKOS)

Corient Private Wealth LLC raised its position in shares of Glaukos Co. (NYSE:GKOSFree Report) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,775 shares of the medical instruments supplier’s stock after acquiring an additional 163 shares during the period. Corient Private Wealth LLC owned approximately 0.05% of Glaukos worth $1,969,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in GKOS. National Bank of Canada FI bought a new position in Glaukos during the 4th quarter valued at about $46,000. GAMMA Investing LLC purchased a new position in shares of Glaukos during the fourth quarter valued at approximately $55,000. Quadrant Capital Group LLC grew its stake in shares of Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 329 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in shares of Glaukos in the fourth quarter worth approximately $216,000. Finally, Pathstone Family Office LLC bought a new stake in shares of Glaukos during the 3rd quarter worth approximately $217,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Up 1.8 %

Shares of Glaukos stock opened at $112.71 on Friday. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. The company has a market cap of $5.68 billion, a P/E ratio of -39.14 and a beta of 1.08. The firm’s 50 day moving average price is $101.42 and its 200-day moving average price is $88.53. Glaukos Co. has a 52-week low of $54.38 and a 52-week high of $115.10.

Glaukos (NYSE:GKOSGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The company had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. During the same quarter last year, the company earned ($0.59) EPS. The business’s revenue was up 15.8% compared to the same quarter last year. On average, sell-side analysts predict that Glaukos Co. will post -2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several research analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $125.00 price objective (up previously from $120.00) on shares of Glaukos in a research report on Thursday, May 2nd. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Citigroup upped their target price on shares of Glaukos from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Wells Fargo & Company raised their target price on shares of Glaukos from $103.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $110.00 price target on shares of Glaukos in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $109.55.

Get Our Latest Report on GKOS

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total transaction of $441,250.00. Following the sale, the director now owns 30,620 shares of the company’s stock, valued at approximately $2,702,215. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $88.25, for a total value of $441,250.00. Following the completion of the transaction, the director now owns 30,620 shares in the company, valued at $2,702,215. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 59,801 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.47, for a total transaction of $6,008,206.47. Following the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at $10,232,367.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,975 shares of company stock worth $7,985,213. Insiders own 6.40% of the company’s stock.

Glaukos Company Profile

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Articles

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.